메뉴 건너뛰기




Volumn 89, Issue 2, 2006, Pages 152-159

A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer

Author keywords

Carboplatin; Docetaxel; Non small cell lung cancer; Quality of life

Indexed keywords

CARBOPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

EID: 33646002331     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (5)

References (20)
  • 1
    • 1242318822 scopus 로고    scopus 로고
    • State-of-the-art chemotherapy for advanced non-small cell lung cancer
    • Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004; 31(Suppl 1): 68-74.
    • (2004) Semin Oncol , vol.31 , Issue.SUPPL. 1 , pp. 68-74
    • Ramalingam, S.1    Belani, C.P.2
  • 3
    • 0028843552 scopus 로고
    • Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
    • Non-small Cell Lung Cancer Collaborative Group
    • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
    • (1995) BMJ , vol.311 , pp. 899-909
  • 4
    • 0033049103 scopus 로고    scopus 로고
    • Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy
    • Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24: 17-24.
    • (1999) Lung Cancer , vol.24 , pp. 17-24
    • Thongprasert, S.1    Sanguanmitra, P.2    Juthapan, W.3    Clinch, J.4
  • 5
    • 0033950286 scopus 로고    scopus 로고
    • Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
    • Bonomi P, Kim K, Fairclough D, Cella D, Kuler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-31.
    • (2000) J Clin Oncol , vol.18 , pp. 623-631
    • Bonomi, P.1    Kim, K.2    Fairclough, D.3    Cella, D.4    Kuler, J.5    Rowinsky, E.6
  • 6
    • 0031779533 scopus 로고    scopus 로고
    • Randomised study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
    • The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
    • Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, et al. Randomised study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133-41.
    • (1998) J Clin Oncol , vol.16 , pp. 2133-2141
    • Giaccone, G.1    Splinter, T.A.2    Debruyne, C.3    Kho, G.S.4    Lianes, P.5    Van Zandwijk, N.6
  • 7
    • 0028154069 scopus 로고
    • Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
    • Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
    • (1994) J Clin Oncol , vol.12 , pp. 360-367
    • Le Chevalier, T.1    Brisgand, D.2    Douillard, J.Y.3    Pujol, J.L.4    Alberola, V.5    Monnier, A.6
  • 9
    • 0031804718 scopus 로고    scopus 로고
    • Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
    • Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, et al. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 1998; 16: 1948-53.
    • (1998) J Clin Oncol , vol.16 , pp. 1948-1953
    • Zalcberg, J.1    Millward, M.2    Bishop, J.3    McKeage, M.4    Zimet, A.5    Toner, G.6
  • 10
    • 7144229342 scopus 로고    scopus 로고
    • Firstline treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
    • Georgoulias V, Androulakis N, Dimopoulos AM, Kourousis C, Kakolyris S, Papadakis E, et al. Firstline treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 1998; 9: 331-4.
    • (1998) Ann Oncol , vol.9 , pp. 331-334
    • Georgoulias, V.1    Androulakis, N.2    Dimopoulos, A.M.3    Kourousis, C.4    Kakolyris, S.5    Papadakis, E.6
  • 12
    • 0025146178 scopus 로고
    • A randomised study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861
    • Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, et al. A randomised study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 1990; 8: 1556-62.
    • (1990) J Clin Oncol , vol.8 , pp. 1556-1562
    • Klastersky, J.1    Sculier, J.P.2    Lacroix, H.3    Dabouis, G.4    Bureau, G.5    Libert, P.6
  • 13
    • 0034845844 scopus 로고    scopus 로고
    • Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomised phase III study
    • Jelic S, Mitrovic L, Radosavjelic D, Elezar E, Babovic N, Kovcin V, et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomised phase III study. Lung Cancer 2001; 34: 1-13.
    • (2001) Lung Cancer , vol.34 , pp. 1-13
    • Jelic, S.1    Mitrovic, L.2    Radosavjelic, D.3    Elezar, E.4    Babovic, N.5    Kovcin, V.6
  • 14
    • 0000905275 scopus 로고    scopus 로고
    • Randomised pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small-cell lung cancer (NSCLC)
    • Gatzemeier U, Rosell R, Betticher D, Keppler U, Macha HN, Pirker R, et al. Randomised pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small-cell lung cancer (NSCLC). Eur J Cancer 1999; 35(Suppl 4): 246.
    • (1999) Eur J Cancer , vol.35 , Issue.SUPPL. 4 , pp. 246
    • Gatzemeier, U.1    Rosell, R.2    Betticher, D.3    Keppler, U.4    Macha, H.N.5    Pirker, R.6
  • 15
    • 0042413836 scopus 로고    scopus 로고
    • Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
    • Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-24.
    • (2003) J Clin Oncol , vol.21 , pp. 3016-3024
    • Fossella, F.1    Pereira, J.R.2    Von Pawel, J.3    Pluzanska, A.4    Gorbounova, V.5    Kaukel, E.6
  • 16
    • 0021784662 scopus 로고
    • Measuring quality of life: Risks and benefits
    • Schipper H, Levitt M. Measuring quality of life: risks and benefits. Cancer Treat Rep 1985; 69: 1115-23.
    • (1985) Cancer Treat Rep , vol.69 , pp. 1115-1123
    • Schipper, H.1    Levitt, M.2
  • 17
    • 0345593349 scopus 로고
    • Validity and reliability of the modified Functional Living Index-Cancer (T-FLIC) and the modified quality of life (T-QLI) questionnaires
    • Bangkok, Thailand
    • Sanguanmitra P, Juthapan W, Thongprasert S. Validity and reliability of the modified Functional Living Index-Cancer (T-FLIC) and the modified quality of life (T-QLI) questionnaires. In: Proceedings of the 11th Asia Pacific Cancer Conference, Bangkok, Thailand. 1993: 121.
    • (1993) Proceedings of the 11th Asia Pacific Cancer Conference , pp. 121
    • Sanguanmitra, P.1    Juthapan, W.2    Thongprasert, S.3
  • 19
    • 0033735209 scopus 로고    scopus 로고
    • Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer
    • Belani CP, Einzig A, Bonomi P, Dobbs T, Capozzoli MJ, Earhart R, et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 2000; 11: 673-8.
    • (2000) Ann Oncol , vol.11 , pp. 673-678
    • Belani, C.P.1    Einzig, A.2    Bonomi, P.3    Dobbs, T.4    Capozzoli, M.J.5    Earhart, R.6
  • 20
    • 0037348549 scopus 로고    scopus 로고
    • Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A phase II study in Caucasian and Asian patients
    • Millward MJ, Boyer MJ, Lehnert M, Clarke S, Rischin D, Goh BC, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003; 14: 449-54.
    • (2003) Ann Oncol , vol.14 , pp. 449-454
    • Millward, M.J.1    Boyer, M.J.2    Lehnert, M.3    Clarke, S.4    Rischin, D.5    Goh, B.C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.